Emergency Management of Asthma Exacerbation in Patients with Rheumatic Heart Disease

Initial Assessment and Management

The American College of Allergy, Asthma, and Immunology recommends managing asthma exacerbation using standard protocols with oxygen titrated to maintain SaO₂ >95% in patients with coexisting cardiac disease, while monitoring closely for cardiac decompensation 1
The British Thoracic Society suggests assessing severity using objective criteria, including inability to complete sentences in one breath, respiratory rate >25 breaths/min, heart rate >110 beats/min, and peak expiratory flow (PEF) <50% predicted or personal best 2, 3
Life-threatening features include PEF <33% predicted, silent chest, cyanosis, or feeble respiratory effort, bradycardia, hypotension, exhaustion, confusion, or coma, and normal or elevated PaCO₂ (≥42 mmHg) in a breathless patient 2, 3

The American College of Allergy, Asthma, and Immunology recommends administering oxygen via nasal cannula or mask to maintain SaO₂ >95% due to coexisting heart disease, and using pulse oximetry for continuous monitoring 1
The British Thoracic Society suggests using inhaled short-acting beta-agonist as first-line treatment, with nebulized albuterol 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed 1, 4

The American College of Allergy, Asthma, and Immunology recommends administering systemic corticosteroids immediately, with oral prednisolone 30-60 mg in single or divided doses, and continuing for 5-10 days 1, 4
The British Thoracic Society suggests adding ipratropium bromide for severe exacerbations, with nebulized 0.5 mg every 20 minutes for 3 doses, then every 6 hours 1, 4

The American College of Allergy, Asthma, and Immunology recommends baseline electrocardiogram, continuous cardiac rhythm monitoring, and chest radiograph to exclude congestive heart failure, pneumothorax, pneumonia, or pulmonary edema 1
The British Thoracic Society suggests immediate admission for life-threatening features, PEF <33% predicted after treatment, severe features persisting after 1-2 hours of intensive treatment, and PEF <50% predicted after initial treatment 2, 3, 4

The American College of Allergy, Asthma, and Immunology recommends discharging patients who meet all criteria, including PEF ≥70% of predicted or personal best, minimal or absent symptoms, stable oxygen saturation, and stable for 30-60 minutes after last bronchodilator dose 4
The British Thoracic Society suggests continuing oral prednisolone for 5-10 days, initiating or continuing inhaled corticosteroids, and providing written asthma action plan 4